Market Overview:
The global essential thrombocythemia drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of essential thrombocythemia, rising awareness about the disease, and technological advancements in the field of drug development. The global essential thrombocythemia drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into givinostat, idasanutlin, pracinostat, ruxolitinib phosphate (ruxolitinib), and others. On the basis of application,the market is segmented into research center (laboratory), hospital (clinical setting), clinic (outpatient setting), and others. The regional segments are North America(U.S., Canada), Latin America(Mexico Brazil Argentina Chile Peru Colombia Ecuador Costa Rica Panama.), Europe(Germany U.K France Italy Spain Russia Netherlands Sweden Switzerland Turkey Austria Belgium Denmark Ireland Greece Portugal Romania Hungary Czech Republic Poland Slovakia Slovenia Ukraine ), Asia Pacific(China Japan India South Korea Australia Singapore Malaysia Thailand Vietnam Philippines Indonesia New Zealand Taiwan Hong Kong Macau Sri Lanka Pakistan Nepal Bhutan Bangladesh Maldives Myanmar ),and Middle East & Africa.(South Africa Saudi Arabia UAE Qatar Kuwait Bahrain Oman Jordan Lebanon Syria Iraq Iran).
Product Definition:
Essential thrombocythemia (ET) is a rare blood disorder in which the bone marrow makes too many platelets. Platelets are blood cells that help your body stop bleeding. Most people with ET don't have any symptoms. However, some people may have: -headaches -dizziness -bleeding from the nose or gums -easy bruising If you have these symptoms, see your doctor right away. Essential thrombocythemia drug is used to lower platelet count and to prevent clotting in patients with essential thrombocythemia (ET).
Givinostat:
Givinostat is a cyclic adenosine monophosphate (cAMP) inhibitor which was first approved in Europe in 2001. It was later approved for sale across the globe, including the U.S., Japan, India and China, by 2003.
Idasanutlin:
It is a prescription medicine used for the treatment of essential thrombocythemia. It works by increasing the blood flow in the body and helps to reduce pain caused by acute thrombocytopenia (low platelet count). The global idasanutlin market size was valued at USD 743.5 million in 2018 and is expected to grow at a CAGR of XX% over the forecast period, till 2023.
Application Insights:
The research center application segment held the largest share of over 70.0% in 2017. The essential thrombocythemia drug pipeline consists of a large number of molecules that are in various stages of clinical development and have the potential to be used for treating other diseases than ET. This is expected to drive market growth during the forecast period as these molecules have not been extensively studied for their use against other diseases, which provides an opportunity for new product launches during this period.
Clinical trials involve multiple aspects such as design, conduct, analysis and interpretation along with implementation into practice guidelines that can be followed by others researching similar conditions or disorders. Implementation of these trials requires extensive documentation along with adherence to ethical standards set forth by regulatory authorities regarding informed consent and protection from harm/injury during clinical trials pertaining to Essential Thrombocythemia Drug Market drugs (ETDs).
Regional Analysis:
North America dominated the global market in 2017. The presence of key manufacturers, favorable government initiatives, and high adoption rate of essential thrombocythemia drug are some major factors responsible for its large share. In addition, increasing prevalence of cancer is also expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising geriatric population and awareness about early diagnosis in countries such as China & India. Moreover, growing healthcare expenditure by governments along with rising investments by companies for expanding their business operations will boost this region’s growth further on account of rapid economic development coupled with improving healthcare infrastructure in emerging markets such as India & China has led it being named “The Global Health Frontier 2016†by UBS AG (Swiss Financial Services).
Growth Factors:
- Increasing incidence of Essential Thrombocythemia (ET)
- Growing awareness about the disease and its treatment options
- Rising demand for better-quality drugs with fewer side effects
- Technological advancements in drug development and delivery methods
- Growing number of clinical studies on new ET drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Essential Thrombocythemia Drug Market Research Report
By Type
Givinostat, Idasanutlin, Pracinostat, Ruxolitinib Phosphate, Others
By Application
Research Center, Hospital, Clinic, Others
By Companies
AbbVie Inc, Aop Orphan Pharmaceuticals AG, F. Hoffmann-La Roche Ltd, Galena Biopharma Inc, Incyte Corp, Italfarmaco SpA, MEI Pharma Inc, PharmaEssentia Corp
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
165
Number of Tables & Figures
116
Customization Available
Yes, the report can be customized as per your need.
Global Essential Thrombocythemia Drug Market Report Segments:
The global Essential Thrombocythemia Drug market is segmented on the basis of:
Types
Givinostat, Idasanutlin, Pracinostat, Ruxolitinib Phosphate, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research Center, Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie Inc
- Aop Orphan Pharmaceuticals AG
- F. Hoffmann-La Roche Ltd
- Galena Biopharma Inc
- Incyte Corp
- Italfarmaco SpA
- MEI Pharma Inc
- PharmaEssentia Corp
Highlights of The Essential Thrombocythemia Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Givinostat
- Idasanutlin
- Pracinostat
- Ruxolitinib Phosphate
- Others
- By Application:
- Research Center
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Essential Thrombocythemia Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Essential thrombocythemia drug is a medication used to treat people with thrombocytopenia (a condition in which the number of platelets in the blood decreases). Essential thrombocythemia drug helps to increase the number of platelets in the blood.
Some of the major players in the essential thrombocythemia drug market are AbbVie Inc, Aop Orphan Pharmaceuticals AG, F. Hoffmann-La Roche Ltd, Galena Biopharma Inc, Incyte Corp, Italfarmaco SpA, MEI Pharma Inc, PharmaEssentia Corp.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Essential Thrombocythemia Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Essential Thrombocythemia Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Essential Thrombocythemia Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Essential Thrombocythemia Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Essential Thrombocythemia Drug Market Size & Forecast, 2018-2028
4.5.1 Essential Thrombocythemia Drug Market Size and Y-o-Y Growth
4.5.2 Essential Thrombocythemia Drug Market Absolute $ Opportunity
Chapter 5 Global Essential Thrombocythemia Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Essential Thrombocythemia Drug Market Size Forecast by Type
5.2.1 Givinostat
5.2.2 Idasanutlin
5.2.3 Pracinostat
5.2.4 Ruxolitinib Phosphate
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Essential Thrombocythemia Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Essential Thrombocythemia Drug Market Size Forecast by Applications
6.2.1 Research Center
6.2.2 Hospital
6.2.3 Clinic
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Essential Thrombocythemia Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Essential Thrombocythemia Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Essential Thrombocythemia Drug Analysis and Forecast
9.1 Introduction
9.2 North America Essential Thrombocythemia Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Essential Thrombocythemia Drug Market Size Forecast by Type
9.6.1 Givinostat
9.6.2 Idasanutlin
9.6.3 Pracinostat
9.6.4 Ruxolitinib Phosphate
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Essential Thrombocythemia Drug Market Size Forecast by Applications
9.10.1 Research Center
9.10.2 Hospital
9.10.3 Clinic
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Essential Thrombocythemia Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Essential Thrombocythemia Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Essential Thrombocythemia Drug Market Size Forecast by Type
10.6.1 Givinostat
10.6.2 Idasanutlin
10.6.3 Pracinostat
10.6.4 Ruxolitinib Phosphate
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Essential Thrombocythemia Drug Market Size Forecast by Applications
10.10.1 Research Center
10.10.2 Hospital
10.10.3 Clinic
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Essential Thrombocythemia Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Essential Thrombocythemia Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Essential Thrombocythemia Drug Market Size Forecast by Type
11.6.1 Givinostat
11.6.2 Idasanutlin
11.6.3 Pracinostat
11.6.4 Ruxolitinib Phosphate
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Essential Thrombocythemia Drug Market Size Forecast by Applications
11.10.1 Research Center
11.10.2 Hospital
11.10.3 Clinic
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Essential Thrombocythemia Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Essential Thrombocythemia Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Essential Thrombocythemia Drug Market Size Forecast by Type
12.6.1 Givinostat
12.6.2 Idasanutlin
12.6.3 Pracinostat
12.6.4 Ruxolitinib Phosphate
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Essential Thrombocythemia Drug Market Size Forecast by Applications
12.10.1 Research Center
12.10.2 Hospital
12.10.3 Clinic
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Essential Thrombocythemia Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Essential Thrombocythemia Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Essential Thrombocythemia Drug Market Size Forecast by Type
13.6.1 Givinostat
13.6.2 Idasanutlin
13.6.3 Pracinostat
13.6.4 Ruxolitinib Phosphate
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Essential Thrombocythemia Drug Market Size Forecast by Applications
13.10.1 Research Center
13.10.2 Hospital
13.10.3 Clinic
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Essential Thrombocythemia Drug Market: Competitive Dashboard
14.2 Global Essential Thrombocythemia Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie Inc
14.3.2 Aop Orphan Pharmaceuticals AG
14.3.3 F. Hoffmann-La Roche Ltd
14.3.4 Galena Biopharma Inc
14.3.5 Incyte Corp
14.3.6 Italfarmaco SpA
14.3.7 MEI Pharma Inc
14.3.8 PharmaEssentia Corp
